Faculty Profile

Dr. Harriet O. Smith, M.D.

Harriet O. Smith, M.D.

Professor, Department of Obstetrics & Gynecology and Women's Health (Gynecological Oncology)

Professional Interests

A graduate of the University of Georgia and the Medical College of Georgia, Dr. Smith completed her Residency in Obstetrics and Gynecology and Fellowship in Pelvic Surgery at Emory University and Affiliated Hospitals, followed by a Fellowship in Gynecologic Oncology at Albert Einstein College of Medicine and Montefiore Medical Center.   She was recruited to the University of New Mexico Health Sciences Center where she rose to the rank of Tenured Professor and Director of the Division of Gynecologic Oncology and was the founding PI of the New Mexico Gynecologic Oncology Group consortium and the Endometrial Carcinoma Tissue Repository.  Dr Smith is an active member in numerous local, regional, and national academic societies, and active in clinical, translational, an epidemiological research.  An author of some  75 peer review manuscripts and approximately 200 abstracts, book chapters, invited reviews, her current research focuses on the G-Protein Coupled Receptor, GPR30, as an alternate estrogen receptor in the pathogenesis of high risk endometrial and ovarian cancers.  In collaboration with Dr. Pollard, she is conducting a translational protocol evaluating tumor activated macrophages (TAMS) in endometrial and ovarian cancer and founded the Einstein Gynecologic Tissue Repository, and with  Las Alamos investigators, an NIH-funded clinical trial evaluating  noninvasive real time technology for the diagnosis of cervical dysplasia.  Her passion includes mentoring medical students, residents, and fellows caring for patients with these cancers, and gardening.

Selected Publications

(Select publications from 75 peer-reviewed publications and 200+ publications, abstracts, chapters, invited reviews) 

  1. Smith HO, et al. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin C, bleomycin and cisplatin chemotherapy.  Gynecol Oncol 48:11-15 (1993).
  2. (Co-Author) Multimodality therapy in locally advanced cervical cancer. Curr Opin Obstet Gynecol  5(1):92-98 (1993).
  3. (Co-Author) Wadler S, et al. Management of hypocalcemic effects of WR2721 administered on a daily -X- 5 schedule with cisplatin and radiation therapy. J Clin Oncol 11(8):1517-1522 (1993).
  4. Smith HO, et al. Cigarette Smoking--A Risk Factor for Cervical Neoplasia, Physician Assistant  17(3):57-60 (1993).
  5. (Co-Author) SWOG 8902: GM-CSF, carboplatin, cyclophosphamide.  A Phase I Study.  Cancer Chemother Pharmacol  33:340-346 (1994).
  6. Smith HO, et al. Single-use percutaneous intraperitoneal catheters for P32 therapy.  Cancer 73:2633-2637 (1994).
  7. Bockage T, Dressler L, Smith HO, Bartow S.  Unique flow cytometric histogram pattern in molar pregnancies.  Cancer  73:2782-2790 (1994).
  8. Smith HO, et al. Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer.  Eur J Gynaecol Oncol 15 (6):411-417 (1994).
  9. Goldberg GL, Gibbon DG, Smith HO, et al. The clinical impact of chemotherapy induced thrombocytopenia in patients with gynecologic cancer.  J Clin Oncol 12(11):2317-2320 (1994).
  10. Smith HO, et al. The role of colony stimulating factor-1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.  Clin Cancer Research 1:313-325 (1995).
  11. Smith HO, et al.  A prospective randomized comparison of an attached silver-impregnated cuff to prevent central venous catheter associated infection.  Gynecol Oncol  58:92-100 (1995).
  12. Smith HO, et al.  Hormone replacement therapy in the menopause:  A pro opinion. Ca J Clin  46 (6):343-363 (1996).
  13. Schiff M, Becker TM, Smith HO, et al. Ovarian cancer incidence and mortality in New Mexico's American Indian, Hispanic, and Non-Hispanic white women. Cancer Epidemiology Biomarkers & Prevention  5:323-327 (1996).
  14. Smith HO, et al. Vaginal and pelvic floor reconstruction using vertical rectus abdominis myocutaneous flaps: modifications, complications, and sexual function.  Cancer 83:510-520 (1998).
  15. Schiff M, Becker TM, Smith HO, Gilliland FD, Key CR.  Ovarian cancer incidence and mortality in Hispanic women in New Mexico. BioMedicina 1(5):188-190 (1998).
  16. Anderson PS, Smith HO, et al. Colony- stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas.  Gynecol Oncol 74:202-207 (1999).
  17. Smith HO, Tiffany MF*, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the U.S.—A 24-year population-based study. Gynecol Oncol 78:97-105 (2000).
  18. Morris DM, Smith HO, et al. Are antioxidant levels measured immediately postoperatively an indicator of magnitude of injury? Am J Surg 180:212-216 (2000).
  19. Smith HO.  Clinical Management of Ovarian Cancer [Book Review].  N Engl J Med 345:152-153, 2001.
  20. (Senior Author) Webb JC, et al. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 97:701-706 (2001).
  21. PROLOG Gynecologic Oncology and Surgery, 4th Edition, 2001 (One of 8 contributing editors).
  22. Smith HO, et al. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: A Phase II study of the Gynecology Oncology Group. Gynecol Oncol 84:140-144 (2002).
  23. Smith HO, et al. Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine Cervix? LEAD ARTICLE Gynecol Oncol 85(2):229-241, 2002.
  24. Smith HO, et al. Ethnic differences in risk for gestational trophoblastic disease in New Mexico: A 25-year population-based study. Am J Obstet Gynecol 2003;188:357-66.
  25. Khanlian SA, Smith HO, Cole LA. Persistent Low Levels of hCG: A Pre-Malignant Gestational Trophoblastic Disease. Am J Obstet Gynecol 188; 1254-9, 2003.
  26. Smith HO, et al. Trends in Choriocarcinoma in the US: A 27-Year Perspective. Obstet Gynecol 102 (4), 2003.
  27. (Co-author)  SWOG 9324:  Phase II trial of venorelbine in relapsed ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol  2004;95 (3): 506-512.
  28. (Co-author) Paclitaxel and carboplatin with amifostine in advanced, recurrent or refractory endometrial adenocarcinoma:  a Phase II study of the Southwest Oncology Group. Gynecol Oncol 2005; 96(3): 610-615.
  29. Smith HO, et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix:  A Southwest Oncology Group Study.  Int J Gynecol Cancer 2006; 16:298-305.
  30. Smith HO, et al. Incidence and Survival Rates for Female Malignant Germ Cell Tumors. Obstet Gynecol 2006; 107:1075-1085.
  31. Smith, HO, et al. GPR30:  A Novel Indicator of Poor Survival for Endometrial Carcinoma.  Am. J. Obstet. Gynecol. 196(4):386e 1-9; Discussion 386e 9-11, 2007.
  32. (Senior Author), Mourant, JR., et al. In vivo light scattering measurements for detection of precancerous conditions of the cervix.  Gynecol Oncol 105 (2):439-45, 2007.
  33. (Co-Author) Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer 18: 749-757, 2008.
  34. (Co-Author)Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with solid malignancies.  Invest New Drugs Epub Sept 5, 2008.
  35. (CoAuthor) Estrogen action via the transmembrane receptor GPR30. Annu Rev Physiol 2008 70:56-90, 2008.
  36. (Senior Author), Mourant JR, et al.  Detection of HSIL and cancers in cervical tissue by in vivo light scattering.  J Low Genit Tract Dis 13 (4):216-223, 2009.
  37. (Senior Author)  Mourant et al. In vivo light scattering for the detection of precancerous conditions of the cervix. Applied Optics 48(4):A1-A9, 2009.
  38. (Co-Author) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol. Oncol 114(3):480, 2009.
  39. (Co-Author) Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.  Oncology 77 (6):395-9, 2009.
  40. (Co-Author) Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.  Gynecol. Oncol 112 (3):444-449, 2009.
  41. (Co-Author) Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res  2010; 16 (11):2999-3010.
  42. (Senior Author) Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): A pooled analysis.  Gynecol Oncol  (In Press, 2010).

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Montefiore Medical Park
1695 Eastchester Road
Bronx, NY 10461

Tel: 718.405.8082
Fax: 718.405.8016

Research Information